A Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early Breast Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

688

Participants

Timeline

Start Date

September 18, 2020

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Breast Cancer,HER2-positive
Interventions
DRUG

Nab-paclitaxel+ trastuzumab+ patuzumab

Nab-paclitaxel 125mg/m2 (days 1, 8, 15) + Trastuzumab (initial loading dose of 8 mg/kg, subsequent maintenance dose of 6 mg/kg) + Pertuzumab (initial loading dose of 840mg, subsequent maintenance dose of 420mg), every 21 days constitute a cycle.

DRUG

Docetaxel+ carboplatin+ trastuzumab + patuzumab

Docetaxel 75 mg/m2(day 1) + Carboplatin (AUC=6) (day 1) + Trastuzumab (initial loading dose of 8 mg/kg, subsequent maintenance dose of 6 mg/kg) + Pertuzumab (initial loading dose of 840mg, subsequent maintenance dose of 420mg), every 21 days constitute a cycle.

Trial Locations (1)

Unknown

RECRUITING

Henan cancer hospital, Zhengzhou

All Listed Sponsors
lead

Henan Cancer Hospital

OTHER_GOV

NCT04547907 - A Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early Breast Cancer | Biotech Hunter | Biotech Hunter